UK approves GSK's twice-yearly asthma drug

Core Viewpoint - The UK's health regulator has approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged 12 and older, as well as for a chronic inflammatory sinus condition in adults [1] Group 1 - The drug is intended for patients aged 12 and older [1] - It serves as an add-on treatment for asthma [1] - The drug is also approved for a chronic inflammatory sinus condition in adults [1]